¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"extrinsic pathway of coagulation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic pathway
    ´ë»ç°æ·Î
  • pain pathway
    ÅëÁõÀü´Þ·Î
  • pathway
    °æ·Î, Åë·Î
  • subthalamopallidal pathway
    ½Ã»ó¹ØÃ¢¹éÇÙ·Î
  • sensory pathway
    °¨°¢·Î
  • ubiquitin-protease pathway
    À¯ºñÄûƾ´Ü¹éºÐÇØÈ¿¼ÒÅë·Î
  • visual pathway
    ½Ã°¢°æ·Î
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pathway
    °æ·Î, Åë·Î
  • pain pathway
    ÅëÁõÀü´Þ·Î
  • sensory pathway
    °¨°¢·Î
  • subthalamopallidal pathway
    ½Ã»ó¹ØÃ¢¹éÇÙ·Î, ½Ã»óÇÏ´ãⱸ·Î
  • transcellular pathway
    ¼¼Æ÷Ⱦ´Ü°æ·Î
  • visual pathway
    ½Ã°¢°æ·Î
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation necrosis
    ÀÀ°í±«»ç
  • coagulation time
    ÀÀ°í½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • phosphogluconate oxidative pathway
    ±Û·çÄÜ»ê»êÈ­°æ·Î, ÀÎ´ç¿ø»êÈ­°æ·Î(ìÝÓØ ê«ß«ûùÌèÖØ).
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • extrinsic ocular muscles
    ¿Ü¾È±Ù
  • extrinsic system
    ¿ÜÀμº °èÅë(ͧ÷Ö).
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • blood coagulation =b. clotting
    Ç÷¾×ÀÀ°í(?ËôË­).
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü(?ËôË­Ë»Ëø).
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü(¡­ëêͳѦï®).
  • blood coagulation test
    Ç÷¾×ÀÀ°í½ÃÇè (?ËàÌ´).
  • blood coagulation test
    Ç÷¾×ÀÀ°í½ÃÇè (¡­ãËúÐ).
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀÌ»ó(¡­ì¶ßÈ), ÀÀ°íÀå¾Ö(¡­î¡äô).
  • coagulation disorder
    ÀÀ°íÀÌ»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • biosynthetic pathway
    »ýÇÕ¼º°æ·Î(ßæùêà÷ÌèÖØ)
  • branched metabolic pathway
    ºÐÁö´ë»ç°æ·Î(ÝÂò«ÓÛÞóÌèÖØ)
  • central metabolic pathway
    ÁßÃß´ë»ç°æ·Î(ñéõÒÓÛÞóÌèÖØ)
  • C3 pathway
    C3 °æ·Î (ÌèÖØ)
  • C4 pathway
    C4 °æ·Î (ÌèÖØ)
  • cyclic metabolic pathway
    ȸ·Î ´ë»ç°æ·Î(üÞÖØÓÛÞóÌèÖØ)
  • DAP pathway
    "DAP °æ·Î(ÌèÖØ) (ÔÒ) diaminopimelate pathway,"
  • diaminopimelate pathway
    ÀÌ(ì£)¾Æ¹Ì³ëÇǸá»ê °æ·Î(ÌèÖØ)
  • direct oxidation pathway
    "Á÷Á¢»êÈ­°æ·Î(òÁïÈß«ûùÌèÖØ), (ÔÒ) hexose monophosphate shunt"
  • ED pathway
    ED °æ·Î(ÌèÖØ)
  • Embden-Meyerhof pathway
    ¿¥µ§-¸¶À̾îÈ£ÇÁ °æ·Î(ÌèÖØ)
  • Entner-Doudoroff pathway
    ¿£Æ®³Ê-µÎµµ·ÎÇÁ °æ·Î(ÌèÖØ)
  • feeder pathway
    °ø±Þ °æ·Î (ÍêÐåÌèÖØ)
  • fumarate pathway
    Ç»¸¶¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronate pathway
    ±Û·çÅ¥·Ð»ê(ß«) °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HP Hypersensitivity Pneumonitis
  = Extrinsic Allergic Alveolitis
BREASTS bronchopulmonary aspergillosis, radiotherapy, extrinsic allergic alveolitis, ankylosing spondylitis,...
EAA electroacupuncture analgesia; Epilepsy Association of America; essential amino acid; excitatory amin...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
EPA eicosapentaenoic acid; empiric phrase association; Environmental Protection Agency; erect posterior-...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DIC Disseminated intravascular coagulation syndrome
ILC Interstitial Laser Coagulation
LACI Lipoprotein Associated Coagulation Inhibitor
MCT Microwave coagulation therapy
PMCT Percutaneous microwave coagulation therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • coagulation time
    ÀÀ°í ½Ã°£
  • diffuse intravascular coagulation
    ¹ü¹ß¼º Ç÷°ü³» ÀÀ°í
  • electrosurgical coagulation
    Àü±âÀû ¿Ü°ú ÀÀ°í
  • endolaser coagulation
    ´«¼Ó ·¹ÀÌÀú ÀÀ°í
  • pathologic coagulation
    º´Àû ÀÀ°í
  • thermal coagulation
    ¿­ ÀÀ°í
  • afferent neural pathway
    ±¸½É¼º ½Å°æ °æ·Î
    ¸»ÃÊ ºÎÀ§·ÎºÎÅÍ ÁßÃ߽Űæ°è·Î Àü´ÞµÇ´Â ½Å°æ ÀÓÆÞ½º.
  • anterolateral pathway
    Àü¿ÜÃø·Î, Àü¿ÜÃø °æ·Î, Àü¿ÜÃø Åë·Î
    Åë°¢, ¿Â°¢, ³Ã°¢ ¹× µÐÇÑ Ã˰¢ µî ¸¹Àº Á¾·ùÀÇ °¨°¢À» Àü´Þ.
  • ascending pain pathway
    »óÇà µ¿Åë Àü´Þ·Î
  • ascending pathway
    »óÇà·Î, »óÇà °æ·Î
  • biosynthetic pathway
    »ýÇÕ¼º °úÁ¤ °æ·Î
  • central pain transmission pathway
    ÁßÃß¼º ÅëÁõ Àü´Þ °æ·Î, ÁßÃß µ¿ÅëÀü´Þ °æ·Î
  • central pathway
    ÁßÃß¼º °æ·Î, ÁßÃß °æ·Î
  • central somatosensory pathway
    ÁßÃß¼º ü¼º °¨°¢ °æ·Î, ÁßÃß Ã¼¼º °¨°¢ °æ·Î
  • central trigeminal sensory pathway
    ÁßÃß¼º »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î, Á߽ɼº »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
blood coagulation The sequential process by which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.
(12 Dec 1998)
blood coagulation factor inhibitors Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
(12 Dec 1998)
blood coagulation factors Endogenous substances, usually proteins, that participate in the blood coagulation process.
(12 Dec 1998)
blood coagulation tests Laboratory tests for evaluating the individual's clotting mechanism.
(12 Dec 1998)
coagulation 1. <haematology> The process of clot formation.
2. <chemistry> The solidification of a sol into a gelatinous mass, an alteration of a disperse phase or of a dissolved solid which causes the separation of the system into a liquid phase and an insoluble mass called the clot or curd. Coagulation is usually irreversible.
3. <surgery> The disruption of tissue by physical means to form an amorphous residuum, as in electrocoagulation and photocoagulation.
Origin: L. Coagulatio
(18 Nov 1997)
coagulation factor <haematology> Group of plasma protein substances (Factor I-XIII) contained in the plasma, which act in concert to bring about blood coagulation. Many of the factors contain EGF like domains.
(29 Sep 1997)
coagulation factor XI <haematology> A plasma serine protease with an apple domain.
(18 Nov 1997)
coagulation necrosis A type of necrosis in which the affected cells or tissue are converted into a dry, dull, fairly homogeneous eosinophilic mass without nuclear staining, as a result of the coagulation of protein as occurs in an infarct; microscopically, the necrotic process involves chiefly the cells, and remnants of histologic elements (e.g., elastin, collagen, muscle fibres) may be recognizable, as well as "ghosts" of cells and portions of cell membranes; may be caused by heat, ischemia, and other agents that destroy tissue, including enzymes that would continue to alter the devitalised cellular substance.
(05 Mar 2000)
coagulation profile A test which measures the speed of blood coagulation at different steps of the coagulation pathway.
(27 Sep 1997)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation vitamin An obsolete term for vitamin K.
(05 Mar 2000)
whole blood coagulation time Measurement of the time required by whole blood to produce a visible clot. Factors that could influence the test are all but III, vii, and xiii. Activation may be by contact with the glass tube or exposure to diatomaceous earth. Delay of onset of coagulation may be achieved by use of nonwettable plastic or silicone-coated glass tubes. It is used for monitoring heparin therapy and as a bedside screening test for deficiencies in the intrinsic coagulation pathway. "activated coagulation time" is sometimes referred to as act.
(12 Dec 1998)
heat coagulation test A test for measurement of protein in urine; albumin and globulin are coagulated by heat at an acid pH, and the amount of turbidity present provides a qualitative estimation of the degree of proteinuria.
(05 Mar 2000)
disseminated intravascular coagulation <haematology> Complication of septic shock in which endotoxin (from gram-negative bacteria) induces systemic clotting of the blood, probably indirectly through the effect of endotoxin on neutrophils.
It may also develop in other situations where neutrophils become systemically hyperactivated.
Acronym: DIC
(11 Jan 1998)
laser coagulation The coagulation of tissues using lasers. These lasers produce light in the visible green wavelength that is selectively absorbed by haemoglobin, and thus it is possible to seal bleeding blood vessels.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á